Skip to content

Simulations Plus SLP Clinical Operations — Revenue

Similar metrics at other companies

SRT
SRTAClinical — Revenue
$19.79M
Maximus logo
MMSClinical Services — Revenue
$530.81M+5.3%
Fortrea Holdings Inc. logo
FTREClinical Services Segment — Revenue
$636.5M-2.3%
SRT
SRTAOther Clinical — Revenue
$9.95M
The Oncology Institute, Inc. logo
TOIClinical trials & other — Total operating revenue
$813K-60.2%
BillionToOne, Inc.
 logo
BLLNClinical trial support and other services — Revenue
$1.14M+61.0%

Other financials

Income statement

See full
Revenue$24.3M+8.3%
Gross profit$16.1M+23.0%
Operating income$5.6M+108%
Net income$4.5M+47.5%
EPS (diluted)$0.22+46.7%

Balance sheet

See full
Cash & equivalents$25.7M+134%
Total debt$508.0K-36.2%
Total equity$133.8M-29.4%
Total assets$146.5M-27.3%

Cash flow

See full
Operating cash flow$6.4M+13.1%
CapEx$46.0K-30.3%
Free cash flow$6.4M+13.6%

Valuation

See full
Market cap$366.73M+5.2%
Enterprise value$341.51M+6.0%
P/S4.6×+0.2×

Profitability

See full
Gross margin62%+6.7pp
Operating margin-84.3%
Net margin-78%-87.2pp
FCF margin29.5%+14.9pp

Returns & leverage

See full
Return on equity-38.8%-42.8pp
Debt / equity0.0×
Current ratio5.5×+1.1×

Where this comes from

Reported directly by Simulations Plus in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Simulations Plus’s 10-Q, filed April 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Simulations Plus's clinical operations — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Simulations Plus's clinical operations — revenue?
Simulations Plus (SLP) reported clinical operations — revenue of $415K in Q4 2025.
What does clinical operations — revenue mean?
This metric represents the total gross revenue generated from clinical operations, consulting, and contract research services provided to the pharmaceutical and biotechnology industries. It tracks the financial performance of the service-based segment, reflecting the company's ability to monetize its expertise in drug development and clinical trial support. Monitoring this revenue stream helps investors assess the scale and growth trajectory of the company's service-oriented business model.